Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab Regimens in Wet AMD Patients Undergoing Cataract Surgery
NCT03944070Unknown
- Sponsor
- Ophthalmica Eye Institute
- Start
- Jan 2018
- Primary completion
- Jan 2020
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by Ophthalmica Eye Institute. Primary endpoints: Visual acuity change from baseline at 12 months and Difference in the number of injections at 12 months. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03944070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944070.